PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21424111-6 2011 Matrix metalloproteinase-2 (MMP-2) reduction and nuclear factor-kappaB (NF-kappaB) activation induced by bisphosphonates in HUVECs were also blocked by APC treatment. Diphosphonates 105-120 matrix metallopeptidase 2 Homo sapiens 0-26 28611279-5 2017 Given that MMP-2 is systemically expressed, we used novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitors (BMMPIs) to target the skeletal tissue thereby circumventing potential off-target effects of MMP-2 inhibition outside the bone marrow-tumor microenvironment. Diphosphonates 73-87 matrix metallopeptidase 2 Homo sapiens 11-16 28611279-5 2017 Given that MMP-2 is systemically expressed, we used novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitors (BMMPIs) to target the skeletal tissue thereby circumventing potential off-target effects of MMP-2 inhibition outside the bone marrow-tumor microenvironment. Diphosphonates 73-87 matrix metallopeptidase 2 Homo sapiens 94-99 28611279-5 2017 Given that MMP-2 is systemically expressed, we used novel "bone-seeking" bisphosphonate based MMP-2 specific inhibitors (BMMPIs) to target the skeletal tissue thereby circumventing potential off-target effects of MMP-2 inhibition outside the bone marrow-tumor microenvironment. Diphosphonates 73-87 matrix metallopeptidase 2 Homo sapiens 94-99 23227342-13 2012 With disease progression, MMP-2 expression increases in both mM and surrounding stromal cells, with implications for the use of bisphosphonates or MMP-2 inhibitors. Diphosphonates 128-143 matrix metallopeptidase 2 Homo sapiens 26-31 21714093-2 2011 Here, we report the synthesis and biological evaluation of a new class of MMP inhibitors characterized by a bisphosphonate function as the zinc binding group. Diphosphonates 108-122 matrix metallopeptidase 2 Homo sapiens 74-77 21714093-4 2011 Docking experiments were performed to clarify the mode of binding of bisphosphonate inhibitors in the active site of MMP-2. Diphosphonates 69-83 matrix metallopeptidase 2 Homo sapiens 117-122 21714093-5 2011 The most promising of the studied bisphosphonates showed nanomolar inhibition against MMP-2 and resulted in potent inhibition of osteoclastic bone resorption in vitro. Diphosphonates 34-49 matrix metallopeptidase 2 Homo sapiens 86-91 21424111-6 2011 Matrix metalloproteinase-2 (MMP-2) reduction and nuclear factor-kappaB (NF-kappaB) activation induced by bisphosphonates in HUVECs were also blocked by APC treatment. Diphosphonates 105-120 matrix metallopeptidase 2 Homo sapiens 28-33 9679953-0 1998 Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Diphosphonates 162-176 matrix metallopeptidase 2 Homo sapiens 54-80 11211310-0 2000 Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. Diphosphonates 11-25 matrix metallopeptidase 2 Homo sapiens 44-49 11211310-2 2000 We investigated the role of bisphosphonates, potent inhibitors of bone resorption, on the production of MMP-2 from human osteoblasts. Diphosphonates 28-43 matrix metallopeptidase 2 Homo sapiens 104-109 11211310-4 2000 However, in the presence of physiological concentrations of plasmin, bisphosphonates reduced the amount of MMP-2 in osteoblasts-conditioned media. Diphosphonates 69-84 matrix metallopeptidase 2 Homo sapiens 107-112 11211310-5 2000 Furthermore, bisphosphonates treatment induced degradation of MMP-2 in the presence of plasmin. Diphosphonates 13-28 matrix metallopeptidase 2 Homo sapiens 62-67 11211310-6 2000 Our results indicated that bisphosphonate, a divalent cation chelator, negatively regulated the longevity of MMP-2 in soluble phase plasmin-containing environment. Diphosphonates 27-41 matrix metallopeptidase 2 Homo sapiens 109-114 11211310-7 2000 These findings suggest that bisphosphonates inhibit bone resorption by abrogating MMP-2 protection induced by plasmin-mediated degradation. Diphosphonates 28-43 matrix metallopeptidase 2 Homo sapiens 82-87 19070762-13 2009 CONCLUSIONS: We hypothesize that matrix metalloproteinase 2 (MMP2) is a candidate gene for bisphosphonate-induced ONJ for 3 reasons: 1) MMP2 is associated with bone abnormalities which could be related to ONJ. Diphosphonates 91-105 matrix metallopeptidase 2 Homo sapiens 33-59 19070762-13 2009 CONCLUSIONS: We hypothesize that matrix metalloproteinase 2 (MMP2) is a candidate gene for bisphosphonate-induced ONJ for 3 reasons: 1) MMP2 is associated with bone abnormalities which could be related to ONJ. Diphosphonates 91-105 matrix metallopeptidase 2 Homo sapiens 61-65 19070762-13 2009 CONCLUSIONS: We hypothesize that matrix metalloproteinase 2 (MMP2) is a candidate gene for bisphosphonate-induced ONJ for 3 reasons: 1) MMP2 is associated with bone abnormalities which could be related to ONJ. Diphosphonates 91-105 matrix metallopeptidase 2 Homo sapiens 136-140 19070762-15 2009 3) A network of disorders and disease genes linked by known disorder-gene associations indicates that cardiovascular disease and bone disease are closely related, suggesting that a single drug such as bisphosphonate, acting on a single gene, MMP2, could have both bone and cardiovascular side effects different from the osteoclast inhibition that is characteristic of bisphosphonate. Diphosphonates 201-215 matrix metallopeptidase 2 Homo sapiens 242-246 19070762-15 2009 3) A network of disorders and disease genes linked by known disorder-gene associations indicates that cardiovascular disease and bone disease are closely related, suggesting that a single drug such as bisphosphonate, acting on a single gene, MMP2, could have both bone and cardiovascular side effects different from the osteoclast inhibition that is characteristic of bisphosphonate. Diphosphonates 368-382 matrix metallopeptidase 2 Homo sapiens 242-246 15921672-0 2005 Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. Diphosphonates 139-154 matrix metallopeptidase 2 Homo sapiens 45-78 15046690-7 2002 In patients with metastatic prostate cancer, we are evaluating the addition of the bisphosphonate alendronate when added to ketoconazole for impact on matrix metalloproteinase (MMP)-2 and MMP-9 as well as traditional clinical endpoints. Diphosphonates 83-97 matrix metallopeptidase 2 Homo sapiens 151-183 9626812-3 1998 A potent bisphosphonate compound, alendronate, inhibited MMP-2 secretion to block solubilization of collagen 1. Diphosphonates 9-23 matrix metallopeptidase 2 Homo sapiens 57-62